bevacizumab,panitumumab
amgen,roche,takeda
['bevacizumab', 'gicsm', '#gi', 'crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'paradigm', 'beva']
paradigm trial comparing egfr inhibitor vs. bevacizumab results with crossing os curves, longterm favoring egfr inhibitor as 1st line therapy in crc.
somehow i'm skeptical this is real... #asco22 #gicsm 
GI #Oncologist @ClevelandClinic | @USNews contributor | Tweets my own